Seeking Alpha
  • Friday, October 31, 2014

  • 6:59 PM
    • Herbalife (NYSE:HLF) has settled an 18-month-old class-action suit accusing the company of operating a pyramid scheme. Financial terms are undisclosed; Herbalife says the settlement doesn't feature "an admission of liability or wrongdoing."
    • Former distributor Dana Bostick originally filed the suit, alleging his efforts were "doomed from the start by an Herbalife marketing plan that systematically rewards recruiting over retail sales."
    • Last year, Herbalife amended its distributor agreements to preclude distributors from filing jury and class-action suits.
    | 17 Comments
  • 5:16 PM
    • Alliqua BioMedical (ALQA +3.6%) Q3 results: Revenues: $1.5M (+275.0%); COGS: $0.9M (+50.0%); R&D Expense: $0.6M (+700.0%); SG&A: $5.7M (+171.4%); Operating Loss: ($5.2M) (-126.1%); Net Loss: ($5.1M) (-131.8%); Loss Per Share: ($0.33) (6.5%); Quick Assets: $19.9M (+64.5%).
    • FY14 Guidance: Revenue $4.7M-5M (+160%-180%)
    • FY15 Guidance:Revenue $11M-13M
    • Previously: Alliqua misses by $0.02, beats on revenue
    | Comment!
  • 5:01 PM
    • Endologix (ELGX +1.4%) Q3 results: Global Revenue: $37.2M (+12%); U.S. Revenue $27.1M (+2%); COGS: $13.6M (+84.4%); Gross Profit: $23.6M (63% GM); Operating expenses $32.5M (+15.7%); Net Loss: $(13.9M) (-55%); Loss Per Share: $(0.21) (-50%); Quick Assets: $100.5M (-20.6%).
    • No guidance given.
    • Previously: Endologix EPS in-line, beats on revenue
    | Comment!
  • 4:53 PM
    • Molina Healthcare (MOH +4.6%) Q3 results: Revenues: $2,484.4M (+47.3%); Medical care cost $2,097.8M (+52%); G&A expenses $178.7M (+1.5%); Operating expenses $2,444.6M (+47%); Operating Income: $39.8M (+60%); Net Income: $16.1M (+113%); EPS: $0.33 (+106%); Quick Assets: $1,598.6M (+70.8%); CF Ops: $605.7M (+171%).
    • No Guidance given
    • Previously: Molina Healthcare EPS of $0.33
    | Comment!
  • 4:41 PM
    • Globus Medical (GMED +6.1%) Q3 results: Revenues: $117.8M (+9.9%); Gross Profit: $90.1M (+10.1%); Operating expenses $55.2M (+5.4%); Operating Income: $34.9M (+18.3%); Net Income: $23.1M (+13.5%); EPS: $0.24 (+9.1%); Quick Assets: $298.8M (+25.1%); CF Ops: $77.2M (+27%).
    • No Guidance given.
    • Previously: Globus Medical beats by $0.03, beats on revenue
    | Comment!
  • 4:38 PM
    | Comment!
  • 4:15 PM
    • NuVasive (NUVA +3.8%) Q3 results: Revenues: $189.9M (+12.2%); Gross Profit: $142.2M (+12.9%); Operating expenses $122.8M (+12.4%); Net Loss: $(1.8M) (-124%); Loss Per Share: $(0.04) (-125%); Quick Assets: $300.5 (+22%).
    • FY Guidance revised: Non-GAAP EPS $1.12; Revenue $750M (+10%); GAAP tax expense ~ $7M.
    • Previously NuVasive misses by $0.06, beats on revenue
    | Comment!
  • 3:45 PM
    • BioTelemetry (BEAT +12.1%) Q3 results: Revenues: $43.1M (+35.1%); COGS: $19.4M (+54.0%); R&D Expense: $2M (+5.3%); SG&A: $18.3M (+16.6%); Operating Income: $0.5M (+117.9%); Net Loss: ($29M) (+99.0%); Loss Per Share: ($0.00) (0.0%); Quick Assets: $12.2M (-45.0%); CF Ops: $0.7M (-75.9%).
    • No guidance given.
    | Comment!
  • 3:17 PM
    • PerkinElmer (PKI -0.4%) Q3 results: Revenues: $542M (+3.8%); COGS: $298.7M (+3.4%); R&D Expense: $30.4M (-3.2%); SG&A: $143M (+0.1%); Operating Income: $58.8M (+1.4%); Net Income: $42.3M (+5.2%); EPS: $0.37 (+2.8%); Quick Assets: $203.7M (+17.6%).
    • 2014 Guidance: GAAP EPS: $1.80 - 1.80 from $1.89 - 1.93; non-GAAP EPS: $2.39 - 2.41 from $2.42 - 2.46.
    | Comment!
  • 2:42 PM
    • AbbVie (ABBV +3.7%) surges to a new 52-week high after posting better than expected results in its first earnings report since its mega-merger with Shire fell apart.
    • ABBV also raised its EPS outlook for the year to $3.25-$3.27, up from its prior view for $3.06-$3.16, not including any potential sales from its hepatitis C virus treatment, which is expected to receive approval from U.S. regulators before year's end.
    • While declining to provide details of its marketing and pricing strategy for the treatment, ABBV execs said in today's earnings conference call that the hepatitis C market is bigger and more attractive than it had thought, and expressed confidence the treatment would be able to compete with Gilead's (GILD -2.2%) Sovaldi.
    • Global sales of Humira, the world's top-selling drug, jumped 18% Y/Y to $3.26B; in the U.S., sales surged 25% to $1.74B; the arthritis drug accounted for 65% of total company sales.
    • CEO Richard Gonzalez said ABBV's underlying growth prospects preclude another big merger attempt, but added the company was keen on smaller acquisitions.
    | 6 Comments
  • 2:32 PM
    • OncoGenex Pharmaceuticals (OGXI -0.9%) Q3 results: Revenues: $4.8M (-51.5%); Operating Expenses: $12M (-41.5%); Operating Loss: ($7.2M) (+32.1%); Net Loss: ($4.9M) (+51.0%); Loss Per Share: ($0.23) (+66.2%); Quick Assets: $54.3M (+37.5%).
    • No guidance given.
    | Comment!
  • 2:25 PM
    • Digirad Corp (DRAD +3.9%) Q3 results: Revenues: $13.9M (+12.1%); COGS: $9M (+4.7%); Operating Expenses: $3.2M (+14.3%); Operating Loss: ($16.8M) (-147.1%); Net Loss: ($10M) (-56.3%); Loss Per Share: ($0.26) (-4.0%).
    • 2014 Guidance:The company expects to hit upper end of guidance for revenue $55M, Non-GAAP EPS $0.15, Non-GAAP EBITDA $5M.
    • Previously: Digirad beats by $0.03.
    | 1 Comment
  • 2:03 PM
    • Theravance (THRX +1.6%) Q3 results: Revenues: $1M (+150.0%); Operating Expenses: $10.5M (+29.6%); Operating Loss: ($9.5M) (-23.4%); Net Loss: ($21.3M) (+54.7%); Loss Per Share: ($0.19) (+56.8%); Quick Assets: $310.9M (-40.3%).
    • No guidance given.
    | Comment!
  • 1:26 PM
    • HeartWare International (HTWR +1.5%) Q3 results: Revenues: $68.6M (+25.2%); COGS: $23M (+17.9%); R&D Expense: $29.5M (+13.9%); SG&A: $20.6M (+4.0%); Operating Loss: ($0.8M) (+92.4%); Net Loss: ($7.4M) (+35.1%); Loss Per Share: ($0.43) (+37.7%); Quick Assets: $113.6M (-30.3%).
    • No guidance given.
    | Comment!
  • 1:26 PM
    • Cytokinetics (CYTK -2.4%Q3 results:  Total Revenues: $9.4M (+108.9%); R&D Expense: $11.4M (-14.9%); SG&A: $4.0M (+9.8%); Operating Loss: ($6.0M) (+52.4%); Net Loss: ($6M) (+52.6%); EPS: $(0.16) (+62.8%); Quick Assets: $78.5M (+1%).
    • 2014 Guidance: Cash Revenues: $19M - $21M; Cash R&D Expenses: $45M - $48M; Cash G&A Expenses $15M - $17M.
    | Comment!
  • 12:49 PM
    • ZIOPHARM Oncology (ZIOP +7.8%Q3 results: Revenues: $633K (+216.5%); R&D Expense: $9.7M (+56.5%); SG&A: $2.8M (-9.7%); Operating Loss: $(11.9M) (-30.8%); Net Loss: $(6.1)M (+63.5%); EPS: $-0.06 (+70.0%); Quick Assets: $46.1M (-32.4%).
    • No guidance given.
    | 1 Comment
  • 12:38 PM
    • Mylan (MYL +3.1%Q3 results: Revenues: $2,084M (+17.9%); COGS: $1,071.6M (+11.8%); R&D Expense: $158.2M (+38.8%); SG&A: $418.3M (+19.6%); Operating Income: $495M (+45.7%); Net Income: $499.1M (+214.1%); EPS: $1.26 (+215.0%); Quick Assets: $199.6M (-31.5%); CF Ops: $888.0M (+28.9%).
    • 2014 Guidance: Total revenues: $7.7B - 7.8B from $7.8B - 8.0B; Gross margin: 52% - 53% from 51 - 53%; EBITDA: $2.35b - $2.41B from $2.2B - 2.4B; Net income: $1.4B - 1.44B from $1.265B - 1.370B; Non-GAAP EPS: $3.54 - $3.60 from $3.44 - $3.54; CF Ops: $1.2B - $1.3B from $1.2B - $1.4B; CAPEX: $300M - 350M from $350M - 400M.
    • Q4 Guidance: EBITDA: $660M - $720M: Net income: $410M - $450M; Non-GAAP EPS: $1.03 - $1.09.
    | Comment!
  • 12:25 PM
    • Aegerion Pharmaceuticals (AEGR -41.1%) plummets to 52-week lows after reporting a wider than expected Q3 loss and issuing downside guidance for FY 2014.
    • AEGR now sees 2014 revenues of $150M-$160M from its prior range of $180M-$200M and below $172M analyst consensus estimate, after Q3 sales of its flagship Juxtapid drug fell $5M short of expectations at $44M.
    • Shares are downgraded by at least five firms, including BofA Merrill, which cut its rating all the way down to Underperform from Buy.
    | 1 Comment
  • 11:48 AM
    • Flamel Technologies (FLML -6.8%) Q3 results: Revenues: $7M (+25.0%); COGS: $1.9M (+11.8%); R&D Expense: $7M (+4.5%); SG&A: $4.1M (+41.4%); Operating Loss: ($16.8M) (-147.1%); Net Loss: ($10M) (-56.3%); Loss Per Share: ($0.26) (-4.0%).
    • No guidance given.
    | Comment!
  • 11:41 AM
    | Comment!
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector